Missling has bigger fish to fry than hand holding "the market".... He's working on three FDA trials, and probably helping the FDA debug their new system..
2-73 would be the perfect poster child for a "NEW" FDA. Why do you think we have a 20 year veteran of the FDA as a liason?
And your evidence of Institutions rethinking their positions is what exactly? Though I would hope that Institutions are regularly looking at their positions I don't believe that anyone has information regarding any large holders dropping? What do you have?
The value of his horde of shares lies in FDA or Aussie approval of 2-73 for treatment of disease. Till then the share price is a minor concern. Yes it matters if they have to raise more money, however, that shouldn't happen until after the next series of trials is announced and underway. I expect the share price to rebound on the trials initiation.
Market Data 
Markets 
AI
